Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckPAC: Nivolumab +/- Ipilimumab with SBRT in Pancreatic or Biliary Tract Cancer
NCT02866383Phase 2Completed
- Sponsor
- Herlev Hospital
- Start
- Nov 2016
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in biliary cancer comparing Nivolumab & Radiotherapy with Nivolumab & Ipilimumab & Radiotherapy (2 arms). Primary endpoint: Clinical Benefit Rate at 6 months. Started Nov 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on NCT02866383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02866383.